CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mesenchymal stromal cells and CAR-T cells in regenerative medicine: The homing procedure and their effective parameters.
Mesenchymal stromal cells and CAR-T cells in regenerative medicine: The homing procedure and their effective parameters.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
间充质基质细胞(MSCs)和嵌合抗原受体(CAR)-T细胞是细胞治疗过程中的两个核心要素。MSCs具有显著的免疫调节作用,可减轻组织再生过程中的炎症,而给予特定的趋化因子和黏附分子主要促进CAR-T 细胞向实体瘤的迁移。多种参数影响细胞归巢,包括受者的年龄、细胞传代次数、适当的细胞培养以及递送方式。此外,肿瘤微环境中涉及多种趋化因子,影响归巢过程。本综述讨论了提高细胞归巢效率的参数以及细胞治疗面临的重大挑战。还综述了新兴的综合机制策略,如非系统性和系统性归巢,这些策略在细胞治疗重塑中显示出重要作用。最后,讨论了开发结合MSCs和CAR-T 细胞用于癌症治疗的联合疗法的主要意义。
Mesenchymal stromal cells (MSCs) and chimeric antigen receptor (CAR)-T cells are two core elements in cell therapy procedures. MSCs have significant immunomodulatory effects that alleviate inflammation in the tissue regeneration process, while administration of specific chemokines and adhesive molecules would primarily facilitate CAR-T cell trafficking into solid tumors. Multiple parameters affect cell homing, including the recipient's age, the number of cell passages, proper cell culture, and the delivery method.
In addition, several chemokines are involved in the tumor microenvironment, affecting the homing procedure. This review discusses parameters that improve the efficiency of cell homing and significant cell therapy challenges. Emerging comprehensive mechanistic strategies such as non-systemic and systemic homing that revealed a significant role in cell therapy remodeling were also reviewed.
Finally, the primary implications for the development of combination therapies that incorporate both MSCs and CAR-T cells for cancer treatment were discussed.
MEMBER ACCOUNT
登录成功会直接打开下一页。